ArticleBMC infectious diseases2026
Serological evidence of Lassa virus in commensal rodents from Senegal.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lassa Virus-A Persistent and Evolving Threat.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLassa fever, a neglected zoonotic hemorrhagic disease caused by Lassa virus (LASV) and endemic in West Africa, remains a significant public health concern associated with rodent exposure. Senegal lies at the western fringe of the LASV area, but only one 1988 serosurvey reported low antibody prevalence. Given recent ecological shifts, including the expansion of invasive Rattus rattus and Mus musculus, we reassessed LASV exposure in rodents from Senegal.
methodsWe retrospectively analyzed 618 archived rodent sera collected in 2012-2013 from domestic and peri-domestic environments in central and eastern Senegal. Samples were screened for LASV-specific IgG by ELISA, and IgM was assessed descriptively in IgG-positive or equivocal specimens, with cautious interpretation because rodent validation for IgM remains limited. Spatial mapping and ecological analysis identified seropositivity clusters and potential environmental correlates.
resultsEleven rodents were IgG-seroreactive (1.8%; 95% CI: 0.9-3.2%), and no IgM reactivity was detected, although IgM results were interpreted cautiously because rodent validation remains limited. All seroreactive animals belonged to the commensal species Rattus rattus (9/180; 5%) and Mus musculus (2/174; 1.1%) and were clustered in five villages along major transport corridors. At the locality level, overall positivity ranged from 3.3% to 28.6%, with the highest values observed in Didé Gassama (26.3%) and Kounkane (28.6%), indicating a focal rather than diffuse pattern of LASV exposure.
conclusionsThis study provides the first update in over three decades on LASV exposure in Senegalese rodents. IgG seroreactivity confined to invasive commensal species suggests localized exposure patterns that warrant further investigation, while the weak, non-significant association between rodent diversity and seropositivity does not support a clear diversity effect. Spatial clustering of seropositive rodents along major transport routes points to low-level but persistent circulation in settings favoring human-rodent contact. These findings provide a retrospective baseline of LASV seroreactivity in Senegalese rodents and highlight the need to integrate rodent surveillance into One Health frameworks to strengthen early warning and regional preparedness. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.